In the context of MASLD, hepatic AMPK activity is significantly reduced, while AMPK activation can ameliorate multiple pathological processes including lipid metabolism, inflammatory response, and fibrosis (7). The gene discussed is PRKAA2; the disease is metabolic dysfunction-associated steatotic liver disease.